Bertrand Havrileck - Virbac SA Biologicals RD

All Insiders . France . 
Stock . Virbac SA . Stakeholders . Insider . Bertrand Havrileck
VIRP Stock  EUR 324.00  0.50  0.15%   

Insider

Bertrand Havrileck is Biologicals RD of Virbac SA
Phone33 4 92 08 71 00
Webhttps://corporate.virbac.com

Virbac SA Management Efficiency

The company has return on total asset (ROA) of 0.091 % which means that it generated a profit of $0.091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1542 %, meaning that it generated $0.1542 on every $100 dollars invested by stockholders. Virbac SA's management efficiency ratios could be used to measure how well Virbac SA manages its routine affairs as well as how well it operates its assets and liabilities.
Virbac SA has accumulated 13.15 M in total debt with debt to equity ratio (D/E) of 98.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Virbac SA has a current ratio of 1.21, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist Virbac SA until it has trouble settling it off, either with new capital or with free cash flow. So, Virbac SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Virbac SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Virbac to invest in growth at high rates of return. When we think about Virbac SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MarieHlne FeuilletTrigano SA
74
Pierre BouludBiomerieux SA
52
Heiko ImhlSartorius Stedim Biotech
N/A
Laurent ThoreVetoquinol
N/A
Benedikt OrzelekSartorius Stedim Biotech
N/A
Pierre CharbonnierBiomerieux SA
N/A
Stephan GagneIpsen SA
N/A
Philippe GruetVetoquinol
N/A
Paolo BicciTrigano SA
65
Alexandre MerieuxBiomerieux SA
49
Franois LacosteBiomerieux SA
N/A
Petra KirchhoffSartorius Stedim Biotech
54
Yan MDIpsen SA
56
Frederic BesemeBiomerieux SA
67
Joachim KreuzburgSartorius Stedim Biotech
58
Piet WigerinckIpsen SA
54
Michel FreicheTrigano SA
62
Xavier BerthetVetoquinol
N/A
Franois FeuilletTrigano SA
74
Gwenan WhiteIpsen SA
N/A
Stphane GigouTrigano SA
50
Virbac SA produces and sells medicines and vaccines for companion and food-producing animals. Virbac SA was founded in 1968 and is headquartered in Carros, France. VIRBAC operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 4893 people. Virbac SA (VIRP) is traded on Euronext Paris in France and employs 5,120 people.

Management Performance

Return On Equity0.15
Return On Asset0.091

Virbac SA Leadership Team

Elected by the shareholders, the Virbac SA's board of directors comprises two types of representatives: Virbac SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Virbac. The board's role is to monitor Virbac SA's management team and ensure that shareholders' interests are well served. Virbac SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Virbac SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nathalie Pollet, Head Devel
Marc Bistuer, Head CEO
Sandrine Brunel, Head Communications
Bertrand Havrileck, Biologicals RD
Sebastien Huron, Chairman Board
Habib Ramdani, Deputy CFO
Manuela Rodrguez, Director Projects
Christian Karst, GM Devel
Francesca Cortella, Head HR
Sophie Favini, Head Operations

Virbac Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Virbac SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.15
Return On Asset0.091
Profit Margin0.10 %
Operating Margin0.16 %
Current Valuation2 B
Shares Outstanding8.44 M
Shares Owned By Insiders50.38 %
Shares Owned By Institutions25.03 %
Price To Earning70.83 X
Price To Book2.47 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Other Information on Investing in Virbac Stock

Virbac SA financial ratios help investors to determine whether Virbac Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY